2025年，"钟南山版""张文宏版"等3款国产流感新药陆续上市，打破中国没有原研流感创新药的 纪录。 这些新药把疗效"卷"到了新高度：有的药主打18小时全身症状缓解；有的药与玛巴洛沙韦机制相 同，都主打全程口服一次，1天退烧解毒，退烧时间缩至约22小时。 它们的价格在180元—320元不等，与玛巴洛沙韦的网售价接近。 不过，新药想要取代老药并不容易。 2025年，"钟南山版""张文宏版"等3款国产流感新药陆续上 市，打破中国没有原研流感创新药的纪录。 作者：刘晓诺 封图：图虫创意 一两百元的"流感神药"，不再只有玛巴洛沙韦（速福达）。 当记者向多家药店咨询这些新药时，药师显得茫然，反问记者是否是在找玛巴洛沙韦。 此前多年，在中国，流感最主要的一线用药是奥司他韦，2021年玛巴洛沙韦获批后逐渐成为人们 心中的"流感神药"。 中康科技数据显示，从上市起到2025年10月，国产流感新药的销售额合计不足1000万元。而1月 —10月，奥司他韦和玛巴洛沙韦两种药物合计卖出近85亿元。 有业内人士认为，流感新药在研发上多属于fast-follow（快速跟进）类型，存在同质化问题，还 有机制类似的国产流感新药在等待上市，明 ...

Core Insights - The demand for antiviral drugs has surged during the flu season, with significant increases in sales of Oseltamivir and Marbofloxacin, alongside the recent market entry of three new domestic antiviral drugs [1][3][5] Group 1: Market Demand and Sales Growth - The percentage of flu-like cases in China has risen, with a reported 40.9% positivity rate for flu tests during the 47th week of the year [2] - Sales data from various e-commerce platforms indicate a dramatic increase in antiviral drug demand, with Oseltamivir sales up 4.5 times and Marbofloxacin up 5 times from the previous week [3] - Overall sales of flu-related medications increased by 242% from November 24 to November 30 compared to the previous week, with specific products like Marbofloxacin and Oseltamivir seeing sales increases of 230% and 310%, respectively [3] Group 2: New Drug Approvals and Market Competition - Three new domestic antiviral drugs were approved in 2023, marking a significant increase in competition within the flu medication market [6][8] - The current market is primarily dominated by Oseltamivir and Marbofloxacin, but the entry of new competitors is reshaping the competitive landscape [8][9] - The sales of Oseltamivir reached 59 billion yuan in 2024, maintaining a leading market position despite the influx of generic alternatives [5][9] Group 3: Future Market Trends - The rapid growth of Marbofloxacin is notable, with a projected sales increase of over 758% in 2024, indicating a shift in market dynamics [9] - The competitive landscape is expected to intensify as more domestic companies enter the antiviral drug market, necessitating differentiation through innovation and market segmentation [10]

Group 1: Agricultural Sector - High temperatures and drought conditions are affecting rice production in the Gaochun District, prompting expert intervention to provide guidance on irrigation and fertilization techniques [1] - The project "Straw Matrix Block Rice Simplified Centralized Seedling Cultivation and High-Yield Cultivation Technology Integration Promotion" is being implemented to introduce new varieties and promote efficient cultivation methods [2] - The initiative aims to cultivate local talents who are skilled in technology and operations through training sessions and on-site guidance [2] Group 2: Digital Economy - The project "Multi-Theme, Multi-Level Smart Social Spatiotemporal Data Perception and Fusion Technology Research" by Zhongdian Hongxin Information Technology Co., Ltd. is supported by experts from Nanjing University and Nanjing University of Posts and Telecommunications [2] - The collaboration focuses on overcoming technical challenges related to data fusion in smart society construction, leading to breakthroughs in key technologies [2] Group 3: Health Sector - Nanjing Zhengxiang Pharmaceutical Co., Ltd. is developing a new anti-influenza drug, with expert guidance on clinical trial design and implementation [3] - The drug has received approval for its first indication, adult uncomplicated influenza, and has the potential to replace imported medications in clinical settings [3] Group 4: Expert Service Initiatives - Since 2013, Nanjing has launched expert service initiatives focusing on industrial development, rural revitalization, and public welfare, selecting and funding 141 expert service projects with a total funding of 4.65 million yuan [3] - Future plans include resource integration and strengthening support to enhance the expert service brand project, promoting deep integration of innovation, industry, and talent chains [3]